As you know, estrogen drives the hormone-pooitive breast cancers. The easiest thing I can say now is that AFINITOR closes down the pathway which can get the estrogen receptor to gearing up and there is no other way that there is another pathway. Short and sweet, it is a road block with no way around it.
With this they found increased progression free survival which means that the cancer did not continue to grow. Now like any drug there are side effects and that includes mouth ulcers, fatigue and diarrhea which can be more pronounced in the older patients after 65 and would need to be closely monitored.
This is exciting news as we continue to break new ground. If you want more in depth information though, feel free to go to